Actinium Pharmac Stock Price, News & Analysis

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) presented pivotal data from its Phase 3 SIERRA trial of Iomab-B at the TCT Meeting. The trial demonstrated that 100% of patients receiving Iomab-B accessed bone marrow transplants (BMT) compared to only 18% in the control arm. Additionally, Iomab-B showed lower rates of transplant-related mortality and sepsis. Notably, 82% of the control arm did not achieve the primary endpoint of durable complete remission. Topline results are anticipated in Q3 2022, aiming to bolster Iomab-B's position as a critical therapy for acute myeloid leukemia (AML) patients.

Actinium Pharmaceuticals (ATNM) is set to present updated Phase 3 SIERRA trial data at the TCT Tandem Meetings from April 23-26, 2022. This trial focuses on Iomab-B, a targeted radiotherapy designed for elderly patients with relapsed or refractory acute myeloid leukemia (AML), aiming for successful bone marrow transplants. Early data indicates a 100% access rate to transplantation and improved outcomes compared to conventional therapies. The findings will be showcased by Boglarka Gyurkocza from Memorial Sloan Kettering Cancer Center, highlighting Iomab-B's potential to revolutionize patient treatment pathways.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has entered a licensing agreement with Immedica for Iomab-B, an antibody-radiation conjugate aimed at treating acute myeloid leukemia (AML). Actinium will receive an upfront payment of $35 million and could earn up to $452 million in milestone payments, plus mid-twenty percent royalties on sales. Iomab-B is expected to facilitate bone marrow transplants, addressing a significant medical need in Europe, the Middle East, and North Africa. The Phase 3 SIERRA trial's topline results are anticipated in Q3 2022.

Actinium Pharmaceuticals (NYSE: ATNM) announced promising preclinical results for its anti-HER3 antibody conjugated with Ac-225, aimed at treating HER3-positive non-small cell lung cancer (NSCLC). Studies demonstrated enhanced anti-tumor effects and improved survival in NSCLC models compared to traditional HER3 antibodies. The findings were presented at AACR 2022, emphasizing the potential of HER3-targeted radiotherapy as a novel treatment strategy. Actinium's collaboration with AVEO Oncology further supports the development of this radiotherapy.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) presented preclinical data at the AACR 2022 highlighting the efficacy of combining its Ac-225-HER3 antibody radiation conjugate with Gilead's magrolimab, an anti-CD47 antibody. The study demonstrated significant tumor control improvement in HER3-positive models compared to magrolimab alone. The data suggests enhanced phagocytosis and upregulation of calreticulin, indicating stronger anti-tumor responses. Actinium aims to further develop this combination for treating solid tumors and blood cancers, leveraging its technology and strategic collaborations.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) and AVEO Oncology (NASDAQ: AVEO) announced a research collaboration to develop a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, utilizing Actinium's AWE technology platform with Ac-225. This partnership aims to enhance targeted cell killing in hard-to-treat cancers. AVEO will leverage its expertise in high-affinity antibodies to advance the development of this novel radiotherapy. Both companies are excited about the potential impact on patient outcomes and the expansion of their oncology portfolios.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has partnered with EpicentRx, Inc. to explore the combination of Actimab-A, a targeted radiotherapy, with RRx-001, an immunotherapy targeting the CD47-SIRPα axis, for treating acute myeloid leukemia (AML). This collaboration aims to enhance the immune system's ability to detect and destroy cancer cells. Actinium recently presented data indicating positive outcomes from combining targeted radiotherapy with anti-CD47 antibody treatments. Actinium's ongoing clinical pipeline includes several therapies aimed at improving cancer treatment precision.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presented encouraging results from the Phase 1 Actimab-A and CLAG-M trial at the 63rd ASH Meeting. The trial showed a complete remission rate (CR/CRp) across all dose cohorts and an 80% overall response rate in patients with less than 4 prior therapies. Notably, the MRD negativity rate was 72%, significantly higher than the 39% seen with CLAG-M alone. The study identified 0.75uCi/kg of Actimab-A as the recommended Phase 2 dose with no 30-day mortality reported. These findings bolster plans for future development in AML treatment.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced positive results from the Phase 1 trial of Actimab-A combined with venetoclax for treating relapsed or refractory acute myeloid leukemia (AML). Presented at the 63rd ASH Annual Meeting, the trial showed a 67% overall response rate, including two remissions in patients with a TP53 mutation. Notably, there has been no early mortality in the study. The trial aims to finalize the dosing for the Phase 2 study, addressing the significant unmet need for patients who do not respond to existing therapies.